Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,57€(−29,58%). Der Median liegt bei +6,57€(−29,58%).

Kaufen	6
Halten	3
Verkaufen	0

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

WISeKey's WISeSat Confirms Next Satellite Launch Scheduled for Mid-June from California to Advance Quantum-Safe Space Communications
WISeKey's WISeSat Confirms Next Satellite Launch Scheduled for Mid-June from California to Advance Quantum-Safe Space Communications» Mehr auf globenewswire.com
Quantum Announces Leadership Changes
SAN JOSE, Calif.--(BUSINESS WIRE)--Quantum Corporation (Nasdaq: QMCO) ("Quantum" or the "Company"), a leader in solutions for AI and unstructured data, today announced leadership changes supporting its efforts to transform Quantum's ability to deliver consistent profitability and growth. The Company appointed Hugues Meyrath as its new Chief Executive Officer, effective June 2. Meyrath is a storage industry veteran with over 30 years of experience, most of which includes affiliation with Quantum.» Mehr auf businesswire.com
Quantum BioPharma Clarifies It Has Not Changed Its Name
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces its response to information about certain stock trading platforms as well as misinformation being circulated on certain social media channels. Certain stock trading platforms mistakenly have the Quantum BioPharma name changed to Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) after the news release was issued on May 29, 2025. Quantum BioPharma has not changed its name.» Mehr auf globenewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Quantum einen Umsatz von 69,72 Mio€ und ein Nettoeinkommen von −68,65 Mio€

(EUR)	Dez. 2024	YOY
Umsatz	+69,72 Mio	7,16%
Bruttoeinkommen	+30,52 Mio	15,61%
Nettoeinkommen	−68,65 Mio	668,95%
EBITDA	−60,96 Mio	2.057,03%

Fundamentaldaten

Metrik	Wert
Marktkapitalisierung	+68,90 Mio€
Anzahl Aktien	6,53 Mio
52 Wochen-Hoch/Tief	+79,37€ - +1,94€
Dividenden	Nein
Beta	2,73
KGV (PE Ratio)	−0,47
KGWV (PEG Ratio)	0,00
KBV (PB Ratio)	−0,30
KUV (PS Ratio)	+0,28